KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for ClearPoint Neuro (CLPT) over the last 13 years, with Q3 2025 value amounting to $38.2 million.

  • ClearPoint Neuro's Cash & Equivalents rose 7717.05% to $38.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.2 million, marking a year-over-year increase of 7717.05%. This contributed to the annual value of $20.1 million for FY2024, which is 1312.01% down from last year.
  • According to the latest figures from Q3 2025, ClearPoint Neuro's Cash & Equivalents is $38.2 million, which was up 7717.05% from $41.5 million recorded in Q2 2025.
  • Over the past 5 years, ClearPoint Neuro's Cash & Equivalents peaked at $64.9 million during Q1 2021, and registered a low of $12.4 million during Q1 2025.
  • Moreover, its 5-year median value for Cash & Equivalents was $27.1 million (2022), whereas its average is $33.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 28375.75% in 2021, then tumbled by 6497.18% in 2025.
  • ClearPoint Neuro's Cash & Equivalents (Quarter) stood at $54.1 million in 2021, then tumbled by 48.96% to $27.6 million in 2022, then dropped by 16.2% to $23.1 million in 2023, then decreased by 13.12% to $20.1 million in 2024, then soared by 90.12% to $38.2 million in 2025.
  • Its Cash & Equivalents stands at $38.2 million for Q3 2025, versus $41.5 million for Q2 2025 and $12.4 million for Q1 2025.